HOME >> MEDICINE >> NEWS
Telemedicine could offer fewer follow-up tests and greater satisfaction for patients

A study in this week's issue of THE LANCET has measured the effects of telemedicine (the use of video-conferencing technology between patients, general practitioners, and specialists), and demonstrated that this new approach to specialist referral from primary care could result in a reduced need for follow-up tests and lead to greater satisfaction among patients.

The conventional system of general practitioner (GP) referral of patients to hospital specialists in the UK is often associated with unnecessary duplication of investigations and treatments. Outreach clinics, in which hospital-based specialists provide outpatient services in primary care, have been established to alleviate this problem, but lack of involvement of GPs is thought to have limited their success. Researchers in the UK have now established "virtual" outreach programmes in which both the patient and GP attend a virtual consultation with a specialist via video conferencing. In the largest ever randomised trial of telemedicine, the Virtual Outreach Project Group, led by Paul Wallace from the Royal Free and University College Medical School, London, UK, compared joint teleconsultations between GPs, specialists, and patients (virtual outreach) with standard outpatient referral.

Virtual outreach services were established in London and Shrewsbury, UK, ensuring a mix of patients from urban and semi-rural settings. This involved patients and GPs communicating with a specialist using a video-conferencing procedure. Around 2100 patients were randomly assigned to receive either a virtual outreach consultation or a standard outpatient appointment arising from conventional referral by GPs. Patients in both groups were followed up for six months.

Unexpectedly, more patients in the virtual outreach group (52%) than the standard group (41%) were offered a follow-up appointment; this effect varied substantially between hospitals and specialties, probably because of specialists' differing n
'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-20-7424-4949
Lancet
6-Jun-2002


Page: 1 2

Related medicine news :

1. Telemedicine revolution is disappearing from the NHS
2. Telemedicine is healthcares new frontier
3. Telemedicine and e-learning put communities in touch
4. Telemedicine could offer fewer follow-up tests and greater satisfaction for patients
5. Telemedicine can be used for accurate diagnosis of stroke symptoms
6. Charcoal and forest management could reduce greenhouse gas levels & save lives in Africa
7. Novel therapy tested in mice could chase away cat allergies
8. Costs of antidepressants could have funded effective alternatives
9. Emergency clopidogrel could save thousands of lives46,000-patient heart attack trial results
10. Blood pressure treatment could cut risk of strokes and heart attacks
11. Proteins found in urine of pregnant women could help diagnose preeclampsia

Post Your Comments:
(Date:4/24/2014)... from The University of Manchester have identified a way ... more open to treatment. , The study published today ... for the development of drugs to target cells that ... made the discovery whilst exploring the possible mechanisms behind ... treat breast and colon cancer. , Dr Andrew Gilmore, ...
(Date:4/24/2014)... with an antimicrobial peptide could help to lower the risk ... Optometry and Vision Science , official journal of the ... published by Lippincott Williams & Wilkins , a part ... and now humans support the biocompatibility and safety of lenses ... research by Debarun Dutta, B.Optom, of The University of New ...
(Date:4/24/2014)... new Institute for Biomedical Sciences at Georgia State ... grant to develop novel therapeutics against Respiratory Syncytial ... Eunice Kennedy Shriver National Institute Of Child Health ... Health will support Plemper,s drug development goals of ... distinct alternative compound. , Infections by RSV, a ...
(Date:4/24/2014)... than one out of three survivors of critical ... The Lancet Respiratory Medicine , and the ... than mentally. , It is one of the ... functional outcomes of critical care survivors, according to ... Medicine, and it highlights a significant public health ...
(Date:4/24/2014)... has found a relationship between motor skill deficiencies and ... in very young children. , The findings, believed ... relationship between motor skills and autism severity, indicate that ... included in treatment plans for young children with autism, ... of Public Health and Human Sciences. , "Recognizing ...
Breaking Medicine News(10 mins):Health News:Scientists find way to target cells resistant to chemo 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 3Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Motor skill deficiencies linked to autism severity in new research 2
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
Cached News: